Iguratimod or T-614 Rheumatoid Arthritis Treatment Market Forecast and Analysis to 2023
Iguratimod (T-614) was approved in Japan in June 2012, and was subsequently launched the following September for the treatment of adults with active RA as an add-on to MTX in patients who are not adequately controlled by monotherapy (Eisai, press release, September 11, 2012). It was also approved in China in 2012. Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in...
View full press release